US Off-Patent Legislation Could Save Over $1bn In Ten Years
Both Bipartisan Bills Were Introduced To The Senate Judiciary Committee Last Year
If passed, the two bills favoring generics and biosimilar developers would not only result in federal savings but would also lead to earlier market entry for off-patent drugs.
